In case you missed it... Q&As About COVID-19 Therapeutics: Which to Use, When to Use, and with Whom?

Last week’s AMDA COVID-19 Grand Rounds: Pearls from Your Colleagues, held on February 17, featured knowledgeable experts who skillfully addressed many of our questions around optimal treatments for COVID-19 patients in post-acute and long-term care (PALTC) settings.

Here are the key Pearls from the session:

1. Paxlovid and Sotrovimab are the best treatment options for patients in PALTC, with Paxlovid being slightly preferred by the consultant pharmacists and infectious disease physician on the panel.

2. Paxlovid has many drug interactions that need to be considered and managed before the treatment can be started. Your best option is close collaboration with your pharmacist to do an immediate Drug Interaction Review. The Liverpool website (https://www.covid19-druginteractions.org/) is also a great resource to identify drug interactions.

3. If you need to hold medications during the treatment, hold medications for the subsequent 3 days post-treatment (total of 8 days).

4. The new mAB Bebtelovimab has no outcome data and should not be utilized if other options are available.

5. Remember, collaboration with your consulting pharmacist has never been more important – know who they are and how you can reach them.

You can access the NIH treatment guidelines here.

Click here to access the recorded webinar. Access is free for AMDA members and $49 for non-members. CME and CMD credit is available to anyone who registers.

Sabine von Preyss-Friedman, MD, FACP CMD
Moderator, AMDA COVID-19 Grand Rounds: Pearls from Your Colleagues